Founder and CEO of Alithea Bio, a German deep-tech biotech company working to make cancer immunotherapies safer and more targeted through immunopeptidomics, proprietary human tissue data, and machine learning. With 15 years of experience in international business development, Fanny brings deep expertise in market entry, strategic partnerships, and commercialization. Under her leadership, Alithea has grown into a commercial biotech company, built partnerships across pharma and biotech, and won both the Tech for Change Jury Prize and Audience Favorite Award at VivaTech 2026.

‍